NTGN

Neon Therapeutics, Inc.

A biotech company that made personalized cancer therapies, designing treatments that train a patient's immune system to fight the specific 'neoantigens' — the unique mutations found in that person's tumor. Founded in 2015 by venture firm Third Rock Ventures, its science grew out of work at Dana-Farber Cancer Institute and the Broad Institute. Its name echoes the word 'neoantigen,' and it lives on today as BioNTech US, the American headquarters of the German biotech that bought it in 2020.

No proxy statement recorded.